Intelligent Bio Solutions — Fiscal First Quarter 2027 Earnings Summary

Intelligent Bio Solutions Inc. reported record fiscal first quarter 2027 revenue of $1.39 million, representing a 25% year-over-year increase and marking the third consecutive quarter of revenue exceeding $1 million. Cartridge sales, which constitute higher-margin recurring revenue, grew 32% year-over-year to account for 61% of total revenue, contributing to an expanded gross profit margin of 54.5%. During the quarter, the company submitted its FDA 510(k) premarket notification for its Intelligent Fingerprinting Drug Screening System and completed its associated clinical program. The company ended the period with $5.93 million in cash and cash equivalents while maintaining an installed base of 1,978 reader units across 516 active customer accounts.